Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
PMDA-Led Inspections Will Help Straighten Up Generic Makers: MHLW Councilor
The Pharmaceuticals and Medical Devices Agency (PMDA) taking over the authority to implement certain GMP inspections from prefectural governments is expected to help boost the quality of generics at large, says a top health ministry officer for pharmaceutical affairs. Discussions…
To read the full story
Related Article
- Advisory Panel Backs Transfer of GMP Inspection Authority for New Generics to PMDA
November 5, 2024
- Panelists Wary of Proposed Switch of Generic GMP Inspection Authority to PMDA
July 8, 2024
- Sato Named MHLW’s Top Pharmacy Officer; Kiyohara to Steer Drug Pricing Reform
July 2, 2024
- JPA Wary of FPMAJ Pitch to Allow Non-Pharmacists as Drug Production Managers
May 21, 2024
REGULATORY
- Japan Sees Limited Impact from Planned US Tariffs on Generics
July 23, 2026
- MHLW Vaccine Panel Advances Mumps, RSV, HPV Discussions
July 23, 2026
- Japan Moves to Bar Duplicate IRB Reviews under Single-IRB Framework
July 23, 2026
- Chuikyo OKs NHI Listing for Cuorips’ iPSC-Based Riheart
July 23, 2026
- Ishin Lawmaker Seeks Full Chuikyo Seat for Industry, but with Fiscal Responsibility
July 22, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…